La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Zai Lab Bilan de santé
Santé financière contrôle des critères 4/6
Zai Lab has a total shareholder equity of $704.2M and total debt of $70.3M, which brings its debt-to-equity ratio to 10%. Its total assets and total liabilities are $987.4M and $283.2M respectively.
Informations clés
10.0%
Ratio d'endettement
US$70.30m
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | US$630.05m |
Fonds propres | US$704.18m |
Total du passif | US$283.19m |
Total des actifs | US$987.37m |
Mises à jour récentes de la santé financière
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Recent updates
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Analyse de la situation financière
Passif à court terme: ZLAB's short term assets ($869.9M) exceed its short term liabilities ($251.7M).
Passif à long terme: ZLAB's short term assets ($869.9M) exceed its long term liabilities ($31.5M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: ZLAB has more cash than its total debt.
Réduire la dette: ZLAB's debt to equity ratio has increased from 1.5% to 10% over the past 5 years.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: ZLAB has sufficient cash runway for more than a year based on its current free cash flow.
Prévisions de trésorerie: Insufficient data to determine if ZLAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.